Compare Moody's Corporation (MCO) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moody's Corporation vs Regeneron Pharmaceuticals Inc — how do they compare? Moody's Corporation trades at $488.42 (market cap $84.59B), while Regeneron Pharmaceuticals Inc trades at $805.87 (market cap $82.98B). The key difference: Moody's Corporation and Regeneron Pharmaceuticals Inc are close in size by market cap, and Moody's Corporation pays the higher dividend (0.84%). Which is the better fit depends on your goals.
| MCO | REGN | |
|---|---|---|
Market Cap | $84.59B | $82.98B |
Sector | Financials | Health |
52-Week High | $539.61 | $812.27 |
52-Week Low | $412.23 | $555.51 |
Enterprise Value | $90.61B | $77.69B |
Dividend Yield | 0.84% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCO trades at $488.42, up 2.51% in 24 hours, with a neutral technical signal and strong fundamental performance. Recent Q2 2026 earnings beat estimates with EPS of $4.68 versus $4.26 expected, driven by robust debt issuance and analytics demand. Revenue growth accelerated to 15% year-over-year, while profitability remains high with a net margin of 34.25% in 2025. The stock is near resistance at $488, with support at $474.
Outlook is positive given earnings momentum and analyst consensus, but valuation risks persist with a P/E of 30.32. Upside to the $561.88 price target depends on sustained growth in bond markets and AI-driven analytics. Key risks include economic slowdowns impacting issuance volumes and competitive pressures in credit ratings.
Regeneron Pharmaceuticals (REGN) trades at $805.97, up 1.13% in the last session, with a bullish technical signal supported by moving averages. The company shows robust fundamentals, including a P/E of 19.75, net income margin of 27.86%, and consistent earnings beats in recent quarters. However, multiple class-action lawsuits related to Phase 3 trial disclosures for Fianlimab-Libtayo have emerged, creating near-term uncertainty despite strong product performance from Eylea HD and Dupixent.
The outlook remains positive due to solid financials and analyst consensus, but legal risks and high RSI levels suggest caution. Investment opportunities lie in continued earnings growth and pipeline advancements, while risks include litigation outcomes and potential regulatory scrutiny. The stock's current price near resistance at $806 may test investor patience amid mixed sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
